💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Lamotrigine

CHEMBL741 Phase 4 Approved Small molecule
Half-Life
25 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
256.1 g/mol
LogP
1.4
Phase
4

An anticonvulsant and mood stabilizer used to treat epilepsy and bipolar disorder, and studied for potential benefits in Alzheimer's disease. It works by blocking voltage-gated sodium channels and reducing the release of excitatory neurotransmitters.

Molecular Weight

256.0910 g/mol

LogP

1.40

TPSA

90.70 Ų

Lipinski RO5

Pass

Therapeutic Areas

Asthma Bipolar Disorder Chronic Pain Epilepsy Generalized Anxiety Disorder Major Depressive Disorder Migraine Multiple Sclerosis Obesity Pain Management Parkinson's Disease Schizophrenia Stroke

Drug Classes

N — N - Nervous System

Mechanism of Action

Sodium channel blocker inhibiting glutamate release.

Pharmacokinetics (PK)

Half-Life 25 hours

Pharmacodynamics (PD)

Mechanism

Sodium channel blocker inhibiting glutamate release.

2D Structure

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1

                

                

                
                

                    
InChI

                    
InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)

                

                

                

                    
                    

                        
Molecular Formula

                        
C9H7Cl2N5

                    

                    
                    

                        
HBD / HBA

                        
2 / 5

                    

                    
                    

                        
Rotatable Bonds

                        
1

                    

                    
                    
                    

                        
Heavy Atoms

                        
16

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            SCN9A (Sodium Channel Nav1.7)
                            Blocker
                        

                        
                        Primary Target
                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Major


                            
                                Lamotrigine + Valproic Acid
                            
                        

                        
                        
Valproic acid doubles lamotrigine plasma concentrations by inhibiting its glucuronidation; the combination is associated with Stevens-Johnson syndrome and toxic epidermal necrolysis.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Lamotrigine + Sertraline
                            
                        

                        
                        
Sertraline may increase lamotrigine plasma concentrations by inhibiting its glucuronidation, potentially causing lamotrigine toxicity.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Lamotrigine + Acetaminophen
                            
                        

                        
                        
Repeated acetaminophen use may modestly lower lamotrigine plasma levels through induction of UGT glucuronidation pathways, though the clinical impact is generally small.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Lamotrigine + Carbamazepine
                            
                        

                        
                        
Carbamazepine reduces lamotrigine plasma concentrations by approximately 50% through enzyme induction, requiring lamotrigine dose adjustment.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Frequently Asked Questions

                

                    
                    

                        
                        

                            
An anticonvulsant and mood stabilizer used to treat epilepsy and bipolar disorder, and studied for potential benefits in Alzheimer's disease. It works by blocking voltage-gated sodium channels and reducing the release of excitatory neurotransmitters.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Sodium channel blocker inhibiting glutamate release.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Lamotrigine: Half-life: 25 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Lamotrigine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Alprazolam
                            Small molecule
                        
                        
                        
                            Aripiprazole
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL741.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3878.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Medical Disclaimer

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.